Erlei Zhang

842 total citations
61 papers, 562 citations indexed

About

Erlei Zhang is a scholar working on Hepatology, Epidemiology and Oncology. According to data from OpenAlex, Erlei Zhang has authored 61 papers receiving a total of 562 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Hepatology, 26 papers in Epidemiology and 15 papers in Oncology. Recurrent topics in Erlei Zhang's work include Hepatocellular Carcinoma Treatment and Prognosis (35 papers), Liver Disease Diagnosis and Treatment (24 papers) and Liver Disease and Transplantation (16 papers). Erlei Zhang is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (35 papers), Liver Disease Diagnosis and Treatment (24 papers) and Liver Disease and Transplantation (16 papers). Erlei Zhang collaborates with scholars based in China, South Africa and Egypt. Erlei Zhang's co-authors include Zhiyong Huang, Bin-yong Liang, Zunyi Zhang, Xiaoping Chen, Haisu Tao, Huifang Liang, Min Xiong, Keshuai Dong, Jin Gu and Li Jiang and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Scientific Reports.

In The Last Decade

Erlei Zhang

52 papers receiving 557 citations

Peers

Erlei Zhang
Massimo De Giorgio Italy
Yong‐Fa Zhang China
Kongying Lin China
Juxian Sun China
Tsung‐Hui Hu Taiwan
Yadi Liao China
Diyang Xie China
Feng Shen China
Yannan Bai China
Tenyu Motoyama Japan
Massimo De Giorgio Italy
Erlei Zhang
Citations per year, relative to Erlei Zhang Erlei Zhang (= 1×) peers Massimo De Giorgio

Countries citing papers authored by Erlei Zhang

Since Specialization
Citations

This map shows the geographic impact of Erlei Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erlei Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erlei Zhang more than expected).

Fields of papers citing papers by Erlei Zhang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erlei Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erlei Zhang. The network helps show where Erlei Zhang may publish in the future.

Co-authorship network of co-authors of Erlei Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Erlei Zhang. A scholar is included among the top collaborators of Erlei Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erlei Zhang. Erlei Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sun, Hui‐Chuan, Zhiyong Huang, Lianxin Liu, et al.. (2025). Adjuvant Lenvatinib for High-Risk CNLC IIb/IIIa Hepatocellular Carcinoma After Curative Hepatectomy: A Prospective Exploratory Study. Journal of Hepatocellular Carcinoma. Volume 12. 1043–1056.
2.
Lv, Xing, et al.. (2025). Predictive factors and prognostic models for Hepatic arterial infusion chemotherapy in Hepatocellular carcinoma: a comprehensive review. World Journal of Surgical Oncology. 23(1). 166–166. 1 indexed citations
3.
4.
Huang, Zhiyong, et al.. (2024). Nomograms confirm serum IL-6 and CRP as predictors of immune checkpoint inhibitor efficacy in unresectable hepatocellular carcinoma. Frontiers in Immunology. 15. 1329634–1329634. 5 indexed citations
5.
Li, Neng, Erlei Zhang, Xuefeng Zhao, et al.. (2024). The P53–P21–RB1 pathway promotes BRD4 degradation in liver cancer through USP1. Journal of Biological Chemistry. 300(3). 105707–105707. 3 indexed citations
6.
Liao, Zuwei, Kai-Kai Liu, Qin‐Hua Zhao, et al.. (2023). Automatic echocardiographic evaluation of the probability of pulmonary hypertension using machine learning. Pulmonary Circulation. 13(3). e12272–e12272. 10 indexed citations
7.
Jiang, Li, et al.. (2023). Postoperative adjuvant therapy for hepatocellular carcinoma with microvascular invasion. World Journal of Gastrointestinal Surgery. 15(1). 19–31. 9 indexed citations
8.
Liang, Bin-yong, et al.. (2023). HBcAb positivity increases the risk of postoperative complications after extended hemihepatectomy for hilar cholangiocarcinoma. Cancer Medicine. 12(8). 9627–9636. 1 indexed citations
9.
Li, Jian, Wenqiang Wang, Ronghua Zhu, et al.. (2023). Postoperative adjuvant tyrosine kinase inhibitors combined with anti-PD-1 antibodies improves surgical outcomes for hepatocellular carcinoma with high-risk recurrent factors. Frontiers in Immunology. 14. 1202039–1202039. 12 indexed citations
10.
Wang, Wenqiang, Xing Lv, Jian Li, et al.. (2022). Repeat hepatectomy versus microwave ablation for solitary and small (≤3 cm) recurrent hepatocellular carcinoma with early or late recurrence: A propensity score matched study. European Journal of Surgical Oncology. 49(5). 1001–1008. 12 indexed citations
11.
Liang, Bin-yong, Jin Gu, Min Xiong, et al.. (2022). Histological Severity of Cirrhosis Influences Surgical Outcomes of Hepatocellular Carcinoma After Curative Hepatectomy. Journal of Hepatocellular Carcinoma. Volume 9. 633–647. 6 indexed citations
12.
13.
Zhang, Erlei, Qi Cheng, Zhiyong Huang, & Wei Dong. (2021). Revisiting Surgical Strategies for Hepatocellular Carcinoma With Microvascular Invasion. Frontiers in Oncology. 11. 691354–691354. 36 indexed citations
14.
Zhang, Erlei, Li Jiang, Jian Li, et al.. (2021). Sub-Classification of Cirrhosis Affects Surgical Outcomes for Early Hepatocellular Carcinoma Independent of Portal Hypertension. Frontiers in Oncology. 11. 671313–671313. 3 indexed citations
15.
Gu, Jin, Erlei Zhang, Bin-yong Liang, et al.. (2020). Use of Direct Liver Stiffness Measurement in Evaluating the Severity of Liver Cirrhosis in Patients with Hepatocellular Carcinoma. World Journal of Surgery. 44(8). 2777–2783. 3 indexed citations
16.
17.
Zhang, Erlei, et al.. (2017). MicroRNA expression profiling in patients with hepatocellular carcinoma of familial aggregation and hepatitis B virus infection. Oncology Letters. 14(1). 971–976. 4 indexed citations
18.
Liang, Bin-yong, Min Xiong, Erlei Zhang, et al.. (2015). Synergistic suppressive effect of PARP-1 inhibitor PJ34 and HDAC inhibitor SAHA on proliferation of liver cancer cells. Journal of Huazhong University of Science and Technology [Medical Sciences]. 35(4). 535–540. 13 indexed citations
19.
Zhang, Erlei, Bin-yong Liang, Zunyi Zhang, et al.. (2015). Morphologic severity of cirrhosis determines the extent of liver resection in patients with hepatocellular carcinoma and Child-Pugh grade A cirrhosis. Journal of Surgical Research. 200(2). 444–451. 16 indexed citations
20.
Huang, Zhiyong, Bin-yong Liang, Min Xiong, et al.. (2015). Severity of cirrhosis should determine the operative modality for patients with early hepatocellular carcinoma and compensated liver function. Surgery. 159(2). 621–631. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Massimo De Giorgio Breakdown of academic impact, for papers by Yong‐Fa Zhang Breakdown of academic impact, for papers by Kongying Lin Breakdown of academic impact, for papers by Juxian Sun Breakdown of academic impact, for papers by Tsung‐Hui Hu Breakdown of academic impact, for papers by Yadi Liao Breakdown of academic impact, for papers by Diyang Xie Breakdown of academic impact, for papers by Feng Shen Breakdown of academic impact, for papers by Yannan Bai Breakdown of academic impact, for papers by Tenyu Motoyama
Rankless by CCL
2026